Jazz Pharmaceuticals plc: Zanidatamab’s Differentiated Efficacy and Safety Profile & Other Major Drivers

In the Q1 2024 earnings, Jazz Pharmaceuticals reported a year-over-year combined double-digit revenue growth from its key growth drivers including Xywav, Epidiolex, and Rylaze. These assets have significantly contributed to their first-quarter total revenue growth which reached over $900 million. Xywav’s revenue growth rose to 14% year-over-year, signifying the company’s positive trajectory and endurance in the market. Jazz Pharmaceuticals is also optimistic about Epidiolex’s solid demand and blockbuster potential. Their oncological business area continues to thrive as well, boasting a robust 13% year-over-year revenue growth. Additionally, they also managed to surpass $1 billion in their annual oncological revenue for the first time, further cementing their foothold in the industry.